Atara Biotherapeutics, Inc. is a biotechnology company focused on the discovery, development and commercialization of novel T-cell immunotherapies to transform the treatment of cancer and autoimmune disease. Headquartered in South San Francisco, California, Atara leverages its proprietary off-the-shelf allogeneic Epstein-Barr virus (EBV)-directed T-cell platform to generate engineered cell therapies designed to target EBV-driven malignancies and immune-mediated disorders.
The company’s lead product candidate, tabelecleucel, is an off-the-shelf, EBV-specific T-cell therapy in clinical development for the treatment of EBV-positive post-transplant lymphoproliferative disease (PTLD) and other EBV-associated cancers. In addition, Atara is advancing multiple earlier-stage programs, including ATA188 for progressive multiple sclerosis and ATA227 for autoimmune indications, each harnessing the company’s expertise in antigen-specific T-cell biology. Atara’s pipeline is supported by manufacturing and process development capabilities aimed at delivering scalable, cryopreserved cell therapies for global distribution.
Founded in 2012, Atara Biotherapeutics has built a diversified clinical portfolio and established collaborations to advance its therapies across North America, Europe and Asia. The company’s leadership team combines expertise in cell therapy development, regulatory affairs and commercial strategy, guided by President and Chief Executive Officer Pascal Touchon. Through ongoing clinical studies and strategic partnerships, Atara aims to address unmet medical needs in oncology and autoimmune disease with its off-the-shelf T-cell products.
AI Generated. May Contain Errors.
